FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201825847> ?p ?o ?g. }

• W3201825847 endingPage "48.e10" @default.
• W3201825847 startingPage "48.e1" @default.
• W3201825847 abstract "The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis in recipients of haploidentical and fully matched transplantations is on the increase. Published studies have reported an increased incidence of cytomegalovirus (CMV) infection with the use of PTCy. Limited data exist on the incidence and outcomes of infection with non-CMV herpesviruses (NCHV) in this setting. The aim of this study was to evaluate the cumulative incidence of NCHV infections and the association of NCHV infections with transplantation-specific outcomes in recipients of haploidentical transplantation with PTCy (HaploCy), matched sibling donor transplantation with PTCy (SibCy), and matched sibling donor transplantation with calcineurin inhibitor-based prophylaxis (SibCNI). We hypothesized that, like CMV infection, HaploCy recipients of also will have a higher risk of NCHV infections. Using the Center for International Blood and Marrow Transplantation Research database, we analyzed 2765 patients (HaploCy, n = 757; SibCNI, n = 1605; SibCy, n = 403) who had undergone their first hematopoietic stem cell transplantation (HCT) between 2012 and 2017 for acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. The cumulative incidence of NCHV at 6 months post-NCT was 13.9% (99% confidence interval], 10.8% to 17.3%) in the HaploCy group, 10.7% (99% CI, 7.1% to 15%) in the SibCy group, and 5.7% (99% CI, 4.3% to 7.3%) in the Sib CNI group (P < .001). This was due primarily to a higher frequency of human herpesvirus 6 viremia reported in patients receiving PTCy. The incidence of Epstein-Barr viremia was low in all groups, and no cases of post-transplantation lymphoproliferative disorder were seen in either PTCy group. The incidence of NCHV organ disease was low in all 3 cohorts. The development of NCHV infection was associated with increased treatment-related mortality, particularly in the HaploCy group. There was no association with the development of GVHD, relapse, or disease-free survival. Patients in PTCy cohorts who did not develop NCHV infection had lower rates of cGVHD. This study demonstrates that the use of PTCy is associated with an increased risk of NCHV infection. The development of NCHV infection was associated with increased nonrelapse mortality, especially in the HaploCy group. Prospective trials should consider viral surveillance strategies in conjunction with assessment of immune reconstitution for a better understanding of the clinical relevance of viral reactivation in different HCT settings." @default.
• W3201825847 created "2021-10-11" @default.
• W3201825847 creator A5000958441 @default.
• W3201825847 creator A5002455488 @default.
• W3201825847 creator A5002993817 @default.
• W3201825847 creator A5004885286 @default.
• W3201825847 creator A5008162182 @default.
• W3201825847 creator A5008376636 @default.
• W3201825847 creator A5009220447 @default.
• W3201825847 creator A5012718640 @default.
• W3201825847 creator A5017327825 @default.
• W3201825847 creator A5036228481 @default.
• W3201825847 creator A5037782727 @default.
• W3201825847 creator A5038261300 @default.
• W3201825847 creator A5040185213 @default.
• W3201825847 creator A5042915360 @default.
• W3201825847 creator A5043016347 @default.
• W3201825847 creator A5054372182 @default.
• W3201825847 creator A5057832944 @default.
• W3201825847 creator A5061484901 @default.
• W3201825847 creator A5064454163 @default.
• W3201825847 creator A5067531512 @default.
• W3201825847 creator A5068686662 @default.
• W3201825847 creator A5070794158 @default.
• W3201825847 creator A5078036181 @default.
• W3201825847 creator A5082092102 @default.
• W3201825847 creator A5082236040 @default.
• W3201825847 creator A5082333371 @default.
• W3201825847 date "2022-01-01" @default.
• W3201825847 modified "2023-10-17" @default.
• W3201825847 title "Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome" @default.
• W3201825847 cites W1831137467 @default.
• W3201825847 cites W1970308765 @default.
• W3201825847 cites W1981870173 @default.
• W3201825847 cites W1999091319 @default.
• W3201825847 cites W2005401495 @default.
• W3201825847 cites W2007193673 @default.
• W3201825847 cites W2037419754 @default.
• W3201825847 cites W2054647994 @default.
• W3201825847 cites W2067384066 @default.
• W3201825847 cites W2089998734 @default.
• W3201825847 cites W2116483603 @default.
• W3201825847 cites W2120032553 @default.
• W3201825847 cites W2130040182 @default.
• W3201825847 cites W2132387457 @default.
• W3201825847 cites W2151981635 @default.
• W3201825847 cites W2154556302 @default.
• W3201825847 cites W2164143280 @default.
• W3201825847 cites W2336455104 @default.
• W3201825847 cites W2476252746 @default.
• W3201825847 cites W2554963778 @default.
• W3201825847 cites W2621741324 @default.
• W3201825847 cites W2622595018 @default.
• W3201825847 cites W2790276320 @default.
• W3201825847 cites W2793201478 @default.
• W3201825847 cites W2802910188 @default.
• W3201825847 cites W2914426760 @default.
• W3201825847 cites W2914470973 @default.
• W3201825847 cites W2923738051 @default.
• W3201825847 cites W2924378690 @default.
• W3201825847 cites W2952209878 @default.
• W3201825847 cites W2970999010 @default.
• W3201825847 cites W3083855356 @default.
• W3201825847 cites W3089613115 @default.
• W3201825847 cites W3118878111 @default.
• W3201825847 cites W3135137897 @default.
• W3201825847 doi "https://doi.org/10.1016/j.jtct.2021.09.015" @default.
• W3201825847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34587551" @default.
• W3201825847 hasPublicationYear "2022" @default.
• W3201825847 type Work @default.
• W3201825847 sameAs 3201825847 @default.
• W3201825847 citedByCount "15" @default.
• W3201825847 countsByYear W32018258472022 @default.
• W3201825847 countsByYear W32018258472023 @default.
• W3201825847 crossrefType "journal-article" @default.
• W3201825847 hasAuthorship W3201825847A5000958441 @default.
• W3201825847 hasAuthorship W3201825847A5002455488 @default.
• W3201825847 hasAuthorship W3201825847A5002993817 @default.
• W3201825847 hasAuthorship W3201825847A5004885286 @default.
• W3201825847 hasAuthorship W3201825847A5008162182 @default.
• W3201825847 hasAuthorship W3201825847A5008376636 @default.
• W3201825847 hasAuthorship W3201825847A5009220447 @default.
• W3201825847 hasAuthorship W3201825847A5012718640 @default.
• W3201825847 hasAuthorship W3201825847A5017327825 @default.
• W3201825847 hasAuthorship W3201825847A5036228481 @default.
• W3201825847 hasAuthorship W3201825847A5037782727 @default.
• W3201825847 hasAuthorship W3201825847A5038261300 @default.
• W3201825847 hasAuthorship W3201825847A5040185213 @default.
• W3201825847 hasAuthorship W3201825847A5042915360 @default.
• W3201825847 hasAuthorship W3201825847A5043016347 @default.
• W3201825847 hasAuthorship W3201825847A5054372182 @default.
• W3201825847 hasAuthorship W3201825847A5057832944 @default.
• W3201825847 hasAuthorship W3201825847A5061484901 @default.
• W3201825847 hasAuthorship W3201825847A5064454163 @default.
• W3201825847 hasAuthorship W3201825847A5067531512 @default.
• W3201825847 hasAuthorship W3201825847A5068686662 @default.
• W3201825847 hasAuthorship W3201825847A5070794158 @default.
• W3201825847 hasAuthorship W3201825847A5078036181 @default.

• next